BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27737650)

  • 21. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.
    Ferrero S; Pastore A; Scholz CW; Forstpointner R; Pezzutto A; Bergmann L; Trümper L; Finke J; Keller U; Ghione P; Passera R; Hiddemann W; Weigert O; Unterhalt M; Dreyling M
    Leukemia; 2016 Apr; 30(4):984-7. PubMed ID: 26242461
    [No Abstract]   [Full Text] [Related]  

  • 22. Outcome of mantle cell lymphoma patients treated at a single institution over the past decade.
    Hitz F; Diem S; Haile SR; Ess S; Cerny T; Mey U
    Hematol Oncol; 2014 Dec; 32(4):192-6. PubMed ID: 24338732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
    Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
    Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital.
    Bernard M; Tsang RW; Le LW; Hodgson DC; Sun A; Wells W; Kukreti V; Kuruvilla J; Crump M; Gospodarowicz MK
    Leuk Lymphoma; 2013 Feb; 54(2):261-7. PubMed ID: 22793378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
    Evens AM; Winter JN; Hou N; Nelson BP; Rademaker A; Patton D; Singhal S; Frankfurt O; Tallman MS; Rosen ST; Mehta J; Gordon LI
    Br J Haematol; 2008 Feb; 140(4):385-93. PubMed ID: 18162124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.
    Akhter A; Street L; Ghosh S; Burns BF; Elyamany G; Shabani-Rad MT; Stewart DA; Mansoor A
    Hematol Oncol; 2017 Mar; 35(1):79-86. PubMed ID: 26354285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
    Lenz G; Dreyling M; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of SOX11 immunostaining in confirming the diagnosis of mantle cell lymphoma on fine-needle aspiration samples.
    Zhang YH; Liu J; Dawlett M; Guo M; Sun X; Gong Y
    Cancer Cytopathol; 2014 Dec; 122(12):892-7. PubMed ID: 25056830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
    Eskelund CW; Kolstad A; Jerkeman M; Räty R; Laurell A; Eloranta S; Smedby KE; Husby S; Pedersen LB; Andersen NS; Eriksson M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Workman CT; Garde C; Elonen E; Brown P; Grønbaek K; Geisler CH
    Br J Haematol; 2016 Nov; 175(3):410-418. PubMed ID: 27378674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mantle cell lymphoma epidemiology: a population-based study in France.
    Leux C; Maynadié M; Troussard X; Cabrera Q; Herry A; Le Guyader-Peyrou S; Le Gouill S; Monnereau A
    Ann Hematol; 2014 Aug; 93(8):1327-33. PubMed ID: 24763513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma.
    Pophali PA; Thanarajasingam G
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):971-982. PubMed ID: 32861290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mantle cell lymphoma in the orbital and adnexal region.
    Rasmussen P; Sjö LD; Prause JU; Ralfkiaer E; Heegaard S
    Br J Ophthalmol; 2009 Aug; 93(8):1047-51. PubMed ID: 19429588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should there be a standard therapy for mantle cell lymphoma?
    Smith MR
    Future Oncol; 2011 Feb; 7(2):227-37. PubMed ID: 21345142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indolent mantle cell lymphoma.
    Hsi ED; Martin P
    Leuk Lymphoma; 2014 Apr; 55(4):761-7. PubMed ID: 23927395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.
    Tiemann M; Schrader C; Klapper W; Dreyling MH; Campo E; Norton A; Berger F; Kluin P; Ott G; Pileri S; Pedrinis E; Feller AC; Merz H; Janssen D; Hansmann ML; Krieken H; Möller P; Stein H; Unterhalt M; Hiddemann W; Parwaresch R;
    Br J Haematol; 2005 Oct; 131(1):29-38. PubMed ID: 16173960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mantle cell lymphoma - Current standards of care and future directions.
    Martin P; Ghione P; Dreyling M
    Cancer Treat Rev; 2017 Jul; 58():51-60. PubMed ID: 28651117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
    von Hohenstaufen KA; Conconi A; de Campos CP; Franceschetti S; Bertoni F; Margiotta Casaluci G; Stathis A; Ghielmini M; Stussi G; Cavalli F; Gaidano G; Zucca E
    Br J Haematol; 2013 Aug; 162(4):465-73. PubMed ID: 23808798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
    Epperla N; Switchenko J; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M; Karmali R; Sawalha Y; Hill BT; Ghosh N; Park SI; Bond DA; Hamadani M; Fenske TS; Martin P; Malecek MK; Kahl BS; Flowers CR; Link BK; Kaplan LD; Inwards DJ; Feldman AL; Hsi ED; Maddocks K; Blum KA; Bartlett NL; Cerhan JR; Leonard JP; Habermann TM; Maurer MJ; Cohen JB
    Blood Adv; 2023 Jun; 7(11):2287-2296. PubMed ID: 36516079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.